Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study.

ABSTRACT:

Aims

Semaglutide, a GLP-1 receptor agonist, has shown efficacy in promoting weight loss. However, limited data exist on its impact on lean mass, muscle function, and metabolic adaptations. The SEMALEAN study aims to evaluate these parameters in patients with obesity treated with Semaglutide (2.4 mg).

Materials and methods

This prospective study enrolled 115 patients with obesity between February 2022 and November 2024. Body weight, body composition (measured by DXA), muscle function (handgrip strength), and resting energy expenditure (REE) were assessed at baseline (M0), 7 months (M7), and 12 months (M12). Subgroup analyses examined the impact of sex, type 2 diabetes, previous GLP-1 use, and history of bariatric surgery.

Results

A total of 106 patients (68.9% female;

SUBMITTER: Alissou M 

PROVIDER: S-EPMC12673431 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature